Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

The study marks a new standard for inclusive medicine with recruitment for target demographics reaching over 3x the national average

News | Cardiovascular Clinical Studies

Hawthorne Effect Announces Monumental Diversity in Patient Recruitment Data for Valvular Heart Disease Study

October 10, 2023 — Hawthorne Effect, a complete clinical trials solution, announced interim recruitment results for the ...

October 10, 2023

Primary endpoint, six-month clinical and imaging data from clinical trial of DESyne BDS Plus stent system evaluating safety and efficacy of localized delivery of anticoagulants and an anti-proliferative agent designed to reduce the implant thrombotic risk

News | Stents Drug Eluting

Elixir Medical To Present Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus at TCT 2023

October 10, 2023 — Elixir Medical, a developer of innovative cardiovascular technologies, announced it will present ...

October 10, 2023

The program is recommended by the Centers for Medicare and Medicaid services for patients who undergo heart valve repair or replacement

News | Heart Failure

TAVR: Less Than One-third of Patients Enter Cardiac Rehab After Heart Procedure

October 9, 2023 — The vast majority of people who have a minimally invasive heart valve replacement procedure do not ...

October 09, 2023

Rejuvenate Bio announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key disease-mediating pathways. RJB-0402 demonstrated efficacy in a mouse model of arrhythmogenic cardiomyopathy (ACM)

News | Sudden Cardiac Arrest

Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy

October 9, 2023 — Rejuvenate Bio announced new preclinical efficacy data for RJB-0402, a gene therapy targeting key ...

October 09, 2023

Endotronix announced FDA approval for the PROACTIVE-HF 2 IDE trial with the Cordella Sensor to expand market access and shared positive results from a substudy of their pivotal PROACTIVE-HF clinical trial. The company plans to share full results from the PROACTIVE-HF trial next year.

News | Cardiovascular Clinical Studies

Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial

October 9, 2023 — Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment ...

October 09, 2023

$Retrospective study of over 18,000 drug-refractory AFib patients found those treated with catheter ablation had a 57% lower risk of developing heart failure compared to those receiving antiarrhythmic drugs$

News | Atrial Fibrillation

Biosense Webster Study Links Lower Risk of Heart Failure in Atrial Fibrillation Patients Treated with Catheter Ablation Compared to Antiarrhythmic Drugs

October 6, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

October 06, 2023

According to new research published in Mayo Clinic Proceedings, calculating the patient's mean arterial pressure (AugMAP) is a simple and effective way to identify those patients who may benefit from more aggressive treatment strategies.

News | Structural Heart

Mayo Clinic Researchers Develop Calculation to Identify High-risk Moderate Aortic Stenosis Patients

October 5, 2023 — Mayo Clinic researchers have developed a calculation that can help identify moderate aortic stenosis p ...

October 05, 2023

Beilinson Hospital in Israel used Nanox.AI’s HealthCCSng solution to conduct study on routine chest CT scans to assess impact of AI-based coronary artery calcium (CAC) measurements

News | Computed Tomography (CT)

Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs

September 29, 2023 —Nano-X Imaging, an innovative medical imaging technology company, today announced that HealthCCSng ...

September 29, 2023

Application based on clinically meaningful results from the Phase 3 STELLAR trial

News | Cardiovascular Clinical Studies

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

September 28, 2023 — Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a ...

September 28, 2023

Study participants may transition from the rivaroxaban arm to abelacimab in an extension study

News | Cardiovascular Clinical Studies

Study Confirming Overwhelming Reduction in Bleeding of the Dual-Acting Factor XI/XIa Inhibitor Abelacimab as Compared to Rivaroxaban Selected as Late-Breaker Oral Presentation at the American Heart Association Scientific Sessions

September 26, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for ...

September 26, 2023

Feature | TCT

Cardiovascular Research Foundation Preps Program for Scientific Symposium, TCT 2023

September 26, 2023 — The Cardiovascular Research Foundation's (CRF) annual scientific symposium, the Transcatheter ...

September 26, 2023

Videos | Pharmaceuticals

VIDEO, Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

September 26, 2023

Smidt Heart Institute investigators say condition, apparent resistant hypertension, is common, and a particular medication may get patients’ disease under control

News | Hypertension

Novel Study Deepens Knowledge of Treatment-Resistant Hypertension

September 22, 2023 — For many patients with hypertension--an elevated blood pressure that can lead to stroke or heart ...

September 22, 2023

IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients

News | Hypertension

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients

September 20, 2023 — Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to ...

September 20, 2023

News | Heart Valve Technology

Minneapolis Heart Institute Foundation Launches the PROGRESS Clinical Trial to Examine the Safety and Effectiveness of Transcatheter Valve Replacement in Patients with Moderate, Calcific Aortic Stenosis

September 20, 2023 — The Minneapolis Heart Institute Foundation (MHIF), an internationally renowned cardiovascular ...

September 20, 2023